Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
Rhea-AI Summary
Shuttle Pharmaceuticals, a specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, has announced the issuance of U.S. Patent No. 12,077,515 for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease. The patent, issued on September 3, 2024, covers a series of selective HDAC inhibitors designed to modulate gene expression involved in cancer progression and immune responses.
This patent strengthens Shuttle Pharma's intellectual property portfolio, supporting its efforts to develop novel therapeutics targeting histone deacetylase (HDAC) enzymes. The company's HDAC platform aims to develop cancer immunotherapies and has potential applications in autoimmune, inflammatory, metabolic, neurological, and infectious diseases. Shuttle Pharma now holds over 20 composition of matter HDAC inhibitor patents in the U.S., Canada, and Europe.
Positive
- Issuance of U.S. Patent No. 12,077,515 for Selective Histone Deacetylase Inhibitors
- Strengthened intellectual property portfolio with over 20 HDAC inhibitor patents in U.S., Canada, and Europe
- Potential applications of HDAC platform beyond cancer, including autoimmune and inflammatory diseases
Negative
- None.
News Market Reaction
On the day this news was published, SHPH declined 8.44%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the issuance of U.S. Patent No. 12,077,515, titled “Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease.” This patent was officially issued on September 3, 2024, further strengthening Shuttle Pharma’s intellectual property portfolio and supporting its ongoing efforts to develop novel therapeutics targeting histone deacetylase (HDAC) enzymes.
The newly issued patent covers a series of selective HDAC inhibitors designed to modulate the expression of genes involved in cancer progression, immune responses, and other critical biological pathways. These inhibitors are being developed as potential treatments for a range of human diseases, including cancer.
Shuttle Pharma’s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle Pharma has deployed its proprietary technology to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications. Shuttle Pharma’s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including autoimmune, inflammatory, metabolic, neurological and infectious diseases.
“We are excited to receive this patent, which reflects our commitment to pioneering therapies that address significant unmet medical needs,” said Anatoly Dritschilo, MD, CEO of Shuttle Pharmaceuticals. “These drug candidates were invented by Shuttle Pharma's scientists based on our strategy to selectively inhibit HDAC6 for regulation of the innate immune response to irradiated cancer cells. This achievement underscores Shuttle Pharmaceuticals' role at the forefront of innovative drug development and positions us for further advances in our clinical pipeline.”
Shuttle Pharma now holds more than 20 composition of matter HDAC inhibitor patents in the U.S., Canada and Europe.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2023, as amended, filed with the SEC on September 4, 2024, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
FAQ
What is the new patent issued to Shuttle Pharmaceuticals (SHPH) for?
How many HDAC inhibitor patents does Shuttle Pharma (SHPH) now hold?
What is the main focus of Shuttle Pharmaceuticals (SHPH)?
What potential applications does Shuttle Pharma's (SHPH) HDAC platform have beyond cancer?
